Limits...
Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010.

Ferrer P, Sabaté M, Ballarín E, Fortuny J, Rottenkolber M, Schmiedl S, Laporte JR, Ibáñez L - Springerplus (2015)

Bottom Line: During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly.There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories.The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.

View Article: PubMed Central - PubMed

Affiliation: Fundació Institut Català de Farmacologia, Pg Vall d'Hebron 119-129, 08029 Barcelona, Spain.

ABSTRACT
Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavulanate (AMC) between 2007 and 2010 in the in-and outpatient healthcare setting in 10 European countries provided by IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consumption was expressed in defined daily doses/1000 inhabitants/day (DIDs). We analysed the number of prescriptions by diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD-10). These ICD-10 codes were grouped into four main categories: respiratory infections, genitourinary infections, other infections and other diagnoses. In 2010, the consumption of macrolides and lincosamides ranged from 0.45 DIDs (Sweden) to 5.46 DIDs (Italy), and from 0.04 DIDs (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively in the hospital setting. The consumption of AMC ranged from <0.001 DIDs (Norway) to 11.67 DIDs (Spain). During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly. Macrolides and AMC were mainly prescribed for respiratory infections in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly related with an infection. Lincosamides were prescribed for the respiratory infections and other infections groups. There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories. The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.

No MeSH data available.


Related in: MedlinePlus

Prescription rates (×1000) of lincosamides by diagnostic categories and country, 2008–2010
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4628133&req=5

Fig3: Prescription rates (×1000) of lincosamides by diagnostic categories and country, 2008–2010

Mentions: All countries indicated the use of macrolides for respiratory infections, with a proportion that varied between 33.2 % in United Kingdom and 85.1 % in France. In United Kingdom, macrolides were mainly prescribed for the other diagnoses group. France, Netherlands, Spain and the United Kingdom used lincosamides for other diagnoses group, whereas in Germany and Poland were mainly used for respiratory infections. In Italy, approximately 50 % of the prescriptions of lincosamides were used for other infections. See Figs. 2 and 3 showing the prescription rates of macrolides and lincosamides, respectively, by diagnostic category and country. See Additional files 2 and 3 showing a figure of the prescription rates of erythromycin, clarithromycin, azithromycin and other macrolides by diagnostic category and country.Fig. 2


Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010.

Ferrer P, Sabaté M, Ballarín E, Fortuny J, Rottenkolber M, Schmiedl S, Laporte JR, Ibáñez L - Springerplus (2015)

Prescription rates (×1000) of lincosamides by diagnostic categories and country, 2008–2010
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4628133&req=5

Fig3: Prescription rates (×1000) of lincosamides by diagnostic categories and country, 2008–2010
Mentions: All countries indicated the use of macrolides for respiratory infections, with a proportion that varied between 33.2 % in United Kingdom and 85.1 % in France. In United Kingdom, macrolides were mainly prescribed for the other diagnoses group. France, Netherlands, Spain and the United Kingdom used lincosamides for other diagnoses group, whereas in Germany and Poland were mainly used for respiratory infections. In Italy, approximately 50 % of the prescriptions of lincosamides were used for other infections. See Figs. 2 and 3 showing the prescription rates of macrolides and lincosamides, respectively, by diagnostic category and country. See Additional files 2 and 3 showing a figure of the prescription rates of erythromycin, clarithromycin, azithromycin and other macrolides by diagnostic category and country.Fig. 2

Bottom Line: During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly.There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories.The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.

View Article: PubMed Central - PubMed

Affiliation: Fundació Institut Català de Farmacologia, Pg Vall d'Hebron 119-129, 08029 Barcelona, Spain.

ABSTRACT
Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavulanate (AMC) between 2007 and 2010 in the in-and outpatient healthcare setting in 10 European countries provided by IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consumption was expressed in defined daily doses/1000 inhabitants/day (DIDs). We analysed the number of prescriptions by diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD-10). These ICD-10 codes were grouped into four main categories: respiratory infections, genitourinary infections, other infections and other diagnoses. In 2010, the consumption of macrolides and lincosamides ranged from 0.45 DIDs (Sweden) to 5.46 DIDs (Italy), and from 0.04 DIDs (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively in the hospital setting. The consumption of AMC ranged from <0.001 DIDs (Norway) to 11.67 DIDs (Spain). During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly. Macrolides and AMC were mainly prescribed for respiratory infections in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly related with an infection. Lincosamides were prescribed for the respiratory infections and other infections groups. There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories. The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.

No MeSH data available.


Related in: MedlinePlus